Dermatology Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, Rockefeller Outpatient Pavilion Suite 248, 160 East 53rd Street, New York, NY 10022, USA.
Future Oncol. 2013 Aug;9(8):1161-70. doi: 10.2217/fon.13.62.
In recent years, targeted agents have rapidly evolved as effective tools in the clinical management of a broad range of malignant diseases. These agents disrupt molecular mechanisms and signaling modules that drive the malignant phenotype in defined subsets of malignancies. Beyond the intended cellular targets crucial to tumor growth and progression, these agents also affect signal transduction in normal cells and tissues. The resulting adverse events and their clinical management continue to change, as newer agents with an ever-increasing target spectrum are developed. We provide a succinct overview of dermatologic toxicities arising from the targeting of receptor tyrosine kinases and downstream effectors. Emergent insights into the pathomechanisms involved and the use of this knowledge base to alleviate cutaneous adverse events are discussed.
近年来，靶向药物已迅速发展成为治疗多种恶性疾病的有效手段。这些药物可以破坏驱动特定恶性肿瘤亚群恶性表型的分子机制和信号模块。除了对肿瘤生长和进展至关重要的预期细胞靶点外，这些药物还会影响正常细胞和组织中的信号转导。随着越来越多具有不断增加靶标的新型药物的开发，由此产生的不良事件及其临床管理也在不断变化。我们简要概述了受体酪氨酸激酶及其下游效应物靶向治疗引起的皮肤毒性。讨论了对相关发病机制的新认识，以及利用这一知识库来减轻皮肤不良反应的问题。
